Michelle L O'Donoghue1, Eri T Kato2, Ofri Mosenzon3, Sabina A Murphy4, Avivit Cahn3, Marisol Herrera5, Tsvetalina Tankova6, Alena Šmahelová7, Piera Merlini8, Ingrid Gause-Nilsson9, Anna Maria Langkilde9, Darren K McGuire10, John P H Wilding11, Larry A Leiter12, Deepak L Bhatt4,13, Itamar Raz3, Marc S Sabatine4, Stephen D Wiviott4. 1. TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA. modonoghue@bwh.harvard.edu. 2. Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan. 3. Diabetes Unit, Hadassah Hebrew University Hospital, Jerusalem, Israel. 4. TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA. 5. Torre Medica Providencia, Guadalajara, Mexico. 6. Department of Endocrinology, Medical University, Sofia, Bulgaria. 7. Faculty Hospital Hradec Kralove, Hradec Kralove, Czech Republic. 8. 2nd Division of Cardiology, Ca' Granda Niguarda Hospital, Milan, Italy. 9. BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. 10. Division of Cardiology, University of Texas Southwestern Medical Center, and Parkland Health and Hospital System, Dallas, TX, USA. 11. Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK. 12. Li Ka Shing Knowledge Institute, St Michael's Hospital, University of Toronto, Toronto, ON, Canada. 13. Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.
Abstract
AIMS/HYPOTHESIS: Women remain underrepresented in clinical trials and those with type 2 diabetes mellitus are at high risk for cardiovascular (CV) events. The sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the risk of CV death or heart failure hospitalisations in individuals with type 2 diabetes. Here, we performed a pre-specified analysis to examine whether sex modifies these effects. METHODS: The DECLARE-TIMI 58 trial randomised 17,160 patients with type 2 diabetes with or at risk for atherosclerotic disease to dapagliflozin or placebo (median follow-up 4.2 years). The dual efficacy outcomes were CV death or heart failure hospitalisations, and major adverse cardiovascular events (MACE; CV death, myocardial infarction or ischaemic stroke). The renal-specific composite outcome was a sustained ≥40% drop in eGFR to <60 ml min-1 [1.73 m]-2, new end-stage renal disease or renal death. Cox models were run separately by sex with treatment-by-sex interaction testing for each outcome. RESULTS: At baseline, women (n = 6422, 37.4%) had higher HbA1c, longer type 2 diabetes duration, and were on fewer glucose-lowering medications. There was no evidence of modification of the effect of dapagliflozin by sex for (1) CV death or heart failure hospitalisations: women (3.8% vs 4.5%; HR 0.84, 95% CI 0.66, 1.07) and men (5.3% vs 6.4%; HR 0.83, 95% CI 0.71, 0.96; pinteraction = 0.90); (2) MACE: women (6.3% vs 6.8%; HR 0.93, 95% CI 0.77, 1.12) and men (10.0% vs 10.7%; HR 0.93, 95% CI 0.83, 1.05; pinteraction = 0.99); or (3) renal-specific composite: women (1.4% vs 2.8%; HR 0.50, 95% CI 0.35, 0.70) and men (1.5% vs 2.5%; HR 0.55, 95% CI 0.42, 0.73; pinteraction = 0.64). The overall safety profile of dapagliflozin was similar for women and men. CONCLUSIONS/ INTERPRETATION: Dapagliflozin offers comparable CV and renal benefits and a comparable safety profile in women and men. FUNDING: AstraZeneca. TRIAL REGISTRATION: clinicaltrials.gov NCT01730534.
AIMS/HYPOTHESIS: Women remain underrepresented in clinical trials and those with type 2 diabetes mellitus are at high risk for cardiovascular (CV) events. The sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the risk of CV death or heart failure hospitalisations in individuals with type 2 diabetes. Here, we performed a pre-specified analysis to examine whether sex modifies these effects. METHODS: The DECLARE-TIMI 58 trial randomised 17,160 patients with type 2 diabetes with or at risk for atherosclerotic disease to dapagliflozin or placebo (median follow-up 4.2 years). The dual efficacy outcomes were CV death or heart failure hospitalisations, and major adverse cardiovascular events (MACE; CV death, myocardial infarction or ischaemic stroke). The renal-specific composite outcome was a sustained ≥40% drop in eGFR to <60 ml min-1 [1.73 m]-2, new end-stage renal disease or renal death. Cox models were run separately by sex with treatment-by-sex interaction testing for each outcome. RESULTS: At baseline, women (n = 6422, 37.4%) had higher HbA1c, longer type 2 diabetes duration, and were on fewer glucose-lowering medications. There was no evidence of modification of the effect of dapagliflozin by sex for (1) CV death or heart failure hospitalisations: women (3.8% vs 4.5%; HR 0.84, 95% CI 0.66, 1.07) and men (5.3% vs 6.4%; HR 0.83, 95% CI 0.71, 0.96; pinteraction = 0.90); (2) MACE: women (6.3% vs 6.8%; HR 0.93, 95% CI 0.77, 1.12) and men (10.0% vs 10.7%; HR 0.93, 95% CI 0.83, 1.05; pinteraction = 0.99); or (3) renal-specific composite: women (1.4% vs 2.8%; HR 0.50, 95% CI 0.35, 0.70) and men (1.5% vs 2.5%; HR 0.55, 95% CI 0.42, 0.73; pinteraction = 0.64). The overall safety profile of dapagliflozin was similar for women and men. CONCLUSIONS/ INTERPRETATION: Dapagliflozin offers comparable CV and renal benefits and a comparable safety profile in women and men. FUNDING: AstraZeneca. TRIAL REGISTRATION: clinicaltrials.gov NCT01730534.
Entities:
Keywords:
Cardiovascular outcomes; Clinical trials; SGLT2 inhibitors; Women
Authors: Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi Journal: N Engl J Med Date: 2015-09-17 Impact factor: 91.245
Authors: Christopher P Cannon; Richard Pratley; Samuel Dagogo-Jack; James Mancuso; Susan Huyck; Urszula Masiukiewicz; Bernard Charbonnel; Robert Frederich; Silvina Gallo; Francesco Cosentino; Weichung J Shih; Ira Gantz; Steven G Terra; David Z I Cherney; Darren K McGuire Journal: N Engl J Med Date: 2020-09-23 Impact factor: 176.079
Authors: Agata Ptaszynska; Kristina M Johnsson; Shamik J Parikh; Tjerk W A de Bruin; Anne Marie Apanovitch; James F List Journal: Drug Saf Date: 2014-10 Impact factor: 5.606
Authors: Stephen D Wiviott; Itamar Raz; Marc P Bonaca; Ofri Mosenzon; Eri T Kato; Avivit Cahn; Michael G Silverman; Sameer Bansilal; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John Ph Wilding; Ingrid Am Gause-Nilsson; Anna Maria Langkilde; Peter A Johansson; Marc S Sabatine Journal: Am Heart J Date: 2018-02-07 Impact factor: 4.749
Authors: Amy A Sarma; Eugene Braunwald; Christopher P Cannon; Jianping Guo; KyungAh Im; Elliott M Antman; C Michael Gibson; L Kristin Newby; Robert P Giugliano; David A Morrow; Stephen D Wiviott; Marc S Sabatine; Michelle L O'Donoghue Journal: J Am Coll Cardiol Date: 2019-12-09 Impact factor: 24.094
Authors: Avivit Cahn; Itamar Raz; Marc Bonaca; Ofri Mosenzon; Sabina A Murphy; Ilan Yanuv; Aliza Rozenberg; John P H Wilding; Deepak L Bhatt; Darren K McGuire; Ingrid A M Gause-Nilsson; Martin Fredriksson; Peter A Johansson; Gyorgy Jermendy; Samy Hadjadj; Anna Maria Langkilde; Marc S Sabatine; Stephen D Wiviott; Lawrence A Leiter Journal: Diabetes Obes Metab Date: 2020-04-27 Impact factor: 6.577
Authors: Bernard Zinman; Silvio E Inzucchi; Christoph Wanner; Uwe Hehnke; Jyothis T George; Odd Erik Johansen; David Fitchett Journal: Diabetologia Date: 2018-04-30 Impact factor: 10.122
Authors: Ioanna Gouni-Berthold; Heiner K Berthold; Christos S Mantzoros; Michael Böhm; Wilhelm Krone Journal: Diabetes Care Date: 2008-03-28 Impact factor: 19.112